Abstract
MicroRNAs (miRNAs) are approximately 22-nucleotide noncoding RNAs that constitute silencers of target gene expression and have emerged as key regulatory molecules of mammalian cell functions. Aberrant miRNA expression promotes pathologic conditions including hepatocellular carcinoma (HCC) and a variety of precancerous liver diseases, especially chronic hepatitis B and C, and liver cirrhosis. miRNAs may contribute to HCC development by acting as oncogenes or tumor suppressors. Specific alterations of miRNA expression have also been related to clinical features of HCC, such as stage, differentiation, prognosis, and response to adjuvant therapy. miRNA signatures may help define molecular profiles of liver diseases as biomarkers, and allow classification of different stages of cirrhosis and HCC progression. Either miRNAs, or anti-miRNA oligonucleotides (antagomirs) could be used for in vivo modulation of miRNA actions, and thus have significant potential in molecularly targeted therapy.
Keywords: microRNA, hepatocellular carcinoma, liver diseases, noncoding RNAs, silencers, gene expression, oncogenes, tumor suppressors, antagomirs, targeted therapy
Current Pharmaceutical Design
Title:The Expression Patterns and Clinical Significance of microRNAs in Liver Diseases and Hepatocellular Carcinoma
Volume: 19 Issue: 7
Author(s): Jinsheng Guo and Scott L. Friedman
Affiliation:
Keywords: microRNA, hepatocellular carcinoma, liver diseases, noncoding RNAs, silencers, gene expression, oncogenes, tumor suppressors, antagomirs, targeted therapy
Abstract: MicroRNAs (miRNAs) are approximately 22-nucleotide noncoding RNAs that constitute silencers of target gene expression and have emerged as key regulatory molecules of mammalian cell functions. Aberrant miRNA expression promotes pathologic conditions including hepatocellular carcinoma (HCC) and a variety of precancerous liver diseases, especially chronic hepatitis B and C, and liver cirrhosis. miRNAs may contribute to HCC development by acting as oncogenes or tumor suppressors. Specific alterations of miRNA expression have also been related to clinical features of HCC, such as stage, differentiation, prognosis, and response to adjuvant therapy. miRNA signatures may help define molecular profiles of liver diseases as biomarkers, and allow classification of different stages of cirrhosis and HCC progression. Either miRNAs, or anti-miRNA oligonucleotides (antagomirs) could be used for in vivo modulation of miRNA actions, and thus have significant potential in molecularly targeted therapy.
Export Options
About this article
Cite this article as:
Guo Jinsheng and L. Friedman Scott, The Expression Patterns and Clinical Significance of microRNAs in Liver Diseases and Hepatocellular Carcinoma, Current Pharmaceutical Design 2013; 19 (7) . https://dx.doi.org/10.2174/138161213804805667
DOI https://dx.doi.org/10.2174/138161213804805667 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Role of Alterations in the Apoptotic Machinery in Sensitivity of Cancer Cells to Treatment
Current Pharmaceutical Design Biological Markers in Older People at Risk of Mobility Limitations
Current Pharmaceutical Design Metal Allergens of Growing Significance: Epidemiology, Immunotoxicology, Strategies for Testing and Prevention
Inflammation & Allergy - Drug Targets (Discontinued) PEGylation of Proteins and Liposomes: a Powerful and Flexible Strategy to Improve the Drug Delivery
Current Drug Metabolism Phytochemical and Pharmacological Insight on Sesamol: An Updated Review
Current Bioactive Compounds Therapeutic Potential of Functional MRI in the Squamous Cell Cancer of Head and Neck
Current Medical Imaging Structural Heterogeneity and Multifunctionality of Lactoferrin
Current Protein & Peptide Science Current Protein-based Anti-angiogenic Therapeutics
Mini-Reviews in Medicinal Chemistry Recent Advances in Optical Cancer Imaging of EGF Receptors
Current Medicinal Chemistry Key Roles of MicroRNA-22 Family in Complex Organisms Inferred from its Evolution
MicroRNA Recent Advances of Kinesin Motor Inhibitors and their Clinical Progress
Reviews on Recent Clinical Trials Gene Therapy Approaches to Ataxias
Current Gene Therapy Safety and Utilization of Blood Components as Therapeutic Delivery Systems
Current Pharmaceutical Biotechnology PRAME/EZH2-Mediated Regulation of TRAIL: A New Target for Cancer Therapy
Current Molecular Medicine Meet Our Editorial Board Member
Current Pharmaceutical Biotechnology ROCK Inhibitors as Emerging Therapeutic Candidates for Sarcomas
Current Cancer Drug Targets Retinoid Related Molecules an Emerging Class of Apoptotic Agents with Promising Therapeutic Potential in Oncology: Pharmacological Activity and Mechanisms of Action
Current Pharmaceutical Design CD147 Interacts with NDUFS6 in Regulating Mitochondrial Complex I Activity and the Mitochondrial Apoptotic Pathway in Human Malignant Melanoma Cells
Current Molecular Medicine Advances in Peptide Pharmaceuticals
Current Pharmaceutical Biotechnology Development and Current Status of Unconventional Platinum Anticancer Complexes
Mini-Reviews in Medicinal Chemistry